1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. PRIME MEDICINE INC
Prime Medicine Inc
XNAS: PRME
8.1M
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Prime Medicine Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Prime Medicine Inc share price target, revenues, EPS, net income and more

Prime Medicine Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Prime Medicine Inc Jun-2026 Quarterly Revenue is $1 Million which is growth of 3.5% YoY.

  • POSITIVE

    Quarterly Net Profit Prime Medicine Inc Jun-2026 Quarterly Net Profit is $-42 Million which is growth of 19.9% YoY.

Prime Medicine Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
1.20.90.81.21.11.52.20.20.6
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
44.451.549.555.254.553.946.454.455.748.954.551.545.3
Operating Profit
-43.3-50.7-48.6-54-53.4-52.4-44.2-54.2-55.7-48.3-54.5-51.5-45.3
0.811.11.10.71.21.50.70.6----
Profit Before Tax
-42.1-49.1-46.1-50.6-52.6-51.9-42.3-52.5-55.5-45.6-65.6-50.8-42.4
Tax
-----0.10.1-0.10
⌄
-42.1-49.1-46.1-50.6-52.6-51.9-42.3-52.5-55.3-45.8-65.6-50.7-42.4
Diluted NI Avail to Com Stockholders Ann.
-42.1-49.1-46.1-50.6-52.6-51.9-42.3-52.5-55.3-45.8-65.6-50.7-42.4
Basic EPS
-0.2-0.3-0.2-0.3-0.4-0.4-0.3-0.4-0.5-0.4-0.7-0.6-0.5
Diluted EPS After ExtraOrdinary
-0.2-0.3-0.2-0.3-0.4-0.4-0.3-0.4-0.4-0.5-0.6-0.5-0.5
Number Of Shares End
177.2177.1177.3160.5129.2130.9130.9119.8119.2104.592.591.990.5
Net Income Continuing Discontinued Operations
-42.1-49.1-46.1-50.6-52.6-51.9-42.3-52.5-55.3-45.8-65.6-50.7-42.4
Normalized Income
-37.2-44.5-42.1-39.3-45.8-45.2-36.4-45.9-45.3-42.6-48.3-44.9-39.8
Interest Income
0.811.11.10.71.21.50.70.6----
Interest
-------------
Net Interest Income
0.811.11.10.71.21.50.70.6----
EBIT
-42.9-50.1-47.2-51.7-53.3-53.1-43.8-53.2-56.1-45.6-65.6-50.8-42.4
EBITDA
-41.1-48.3-45.3-49.8-51.5-51.4-42.1-51.7-54.5-44.3-64.4-49.6-41.2
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
1.81.91.91.91.91.71.71.61.51.31.31.21.1
Profit From Continuing Operations
-42.1-49.1-46.1-50.6-52.6-51.9-42.3-52.5-55.3-45.8-65.6-50.7-42.4
Normalized EBITDA
-41.5-48.8-47.3-53.6-51-49.6-42.6-52.9-52.2-48.2-40.4-48.6-44.4
*All financials are in USD Million and price data in USD

Prime Medicine Inc competitor comparison and performance snapshot within industry

Prime Medicine Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Prime Medicine Inc Dec-2025 Annual Revenue is $5 Million which is growth of 55.3% YoY.

  • NEGATIVE

    Annual Net Profit Prime Medicine Inc Dec-2025 Annual Net Profit is $-201 Million which is growth of -2.7% YoY.

Prime Medicine Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20
-
-2.4%
 4.635.2
Cost Of Rev. Ann.
-
-
 ------
Gross Profit Ann.
-
-
 ------
Operating Exp. Ann.
22.3%
103.5%
200.6213205.5191.3116.584.56.1
Operating Profit Ann.
-
-
-196.5-208.4-202.5-191.3-116.5-84.5-0.9
-
-
44.23.5----
Other Exp. Ann.
-
-
 3.13.1-7.1-6.2-81.4-0.6
PBT Ann.
-
-
-187.9-201.1-195.9-198.4-122.8-165.9-1.5
Tax Ann.
-
-
 --0.3-1-0.51.9
⌄
-
-
-187.9-201.1-195.9-198.1-142-184.1-5.1
Diluted NI Avail to Com Stockholders Ann.
-
-
-187.9-201.1-195.9-198.1-142-184.1-5.1
EPS Ann.
-
-
 -1.4-1.7-2.2-1.5-2.6-0.1
Diluted EPS Ann.
-
-
 -1.4-1.7-2.2-1.5-2.6-0.1
Number Of Shares End
22.2%
-
 177.3130.992.597.271.8-
Total Exp. Ann.
22.3%
103.5%
 213205.5191.3116.584.56.1
Net Income Continuing Discontinued Operations Ann.
-
-
-187.9-201.1-195.9-198.1-121.8-165.4-3.4
Normalized Income Ann.
-
-
-163.1-172.3-169.3-168.3-107.3-163.2-11.1
Interest Income Ann.
-
-
44.23.5----
Interest Ann.
-
-
 ------
EBITDA Ann.
-
-
-184.5-198-193.3-193.8-120.6-165.3-1.5
Reconciled Cost Of Rev. Ann.
-
-
 ------
Reconciled Depr. Ann.
49.2%
-
7.47.36.14.72.20.60
Profit From Continuing Operations Ann.
-
-
-187.9-201.1-195.9-198.1-121.8-165.4-3.4
Normalized EBITDA Ann.
-
-
-191.1-201.5-195.9-170.8-106.2-83.5-11.8
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
53.3%
5Y CAGR
-2.4%
Operating Exp. Ann.
1Y CHG
3.6%
2Y CAGR
5.5%
3Y CAGR
22.3%
5Y CAGR
103.5%
Operating Expenses Annual Cr growth is lower than historical averages.

Prime Medicine Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Prime Medicine Inc Dec-2025 Total Shareholders Fund is $121 Million which is growth of -21.1% YoY.

  • POSITIVE

    Total Assets Prime Medicine Inc Dec-2025 Total Assets is $343 Million which is growth of 15.2% YoY.

Prime Medicine Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20
-1.7%
44.3%
342.7297.5193.9360.3301.954.8
⌄
71.5%
59.8%
221.9144.460.84462.321.3
⌄
-27.4%
120.9%
120.9153.2133.1316.3-156.22.3
Total Capitalization Ann.
-27.4%
29.3%
120.9153.2133.1316.3239.633.5
Tangible Assets Ann.
-27.4%
29.3%
120.9153.2133.1316.3239.633.5
Working Capital Ann.
-18.9%
33.4%
143.8173.986.6269.9212.634
Invested Capital Ann.
-27.4%
120.9%
120.9153.2133.1316.3-156.22.3
Tangible Book Value Ann.
-27.4%
120.9%
120.9153.2133.1316.3-156.22.3
Borrowings Ann.
59.5%
-
116.440.813.628.710.4
Net Debt Ann.
-
-
------
Share Issued Ann.
22.9%
13.9%
180.5131.297.497.297.294.3
Number Of Shares End
22.2%
-
177.3130.992.597.271.8-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
15.2%
2Y CAGR
32.9%
3Y CAGR
-1.7%
5Y CAGR
44.3%
Total Assets Annual growth is stable compared to historical averages.
Total Current Liabilities Ann.
1Y CHG
-1.3%
2Y CAGR
-18.5%
3Y CAGR
12%
5Y CAGR
14.1%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-21.1%
2Y CAGR
-4.7%
3Y CAGR
-27.4%
5Y CAGR
120.9%
Total ShareHolders Funds Annual is falling faster than historical averages.

Prime Medicine Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Prime Medicine Inc Book Value Per Share is $11 which is growth of 3128.2% YoY.

  • NEUTRAL

    ROE Prime Medicine Inc ROE is 0% which is growth of 0% YoY.

Prime Medicine Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20
RoA Ann. %
-
-
--79.73%-71.51%-42.89%-103.25%-9.23%
ROE Ann. %
-
-
--136.88%-88.19%-177.48%--216.21%
ROIC %
-
-
--20.6-36.7-52.9--
OPM Ann. %
-
-
-4,498.06%-6,787.36%----17.89%
Inventory Turnover Ratio Ann.
-
-
------
Asset Turnover Ann. %
-
-
-0---0.1
Working Capital Turnover Ann.
-
-
000.2
Quick Ratio Ann.
-
-
-52.2114.72.7
Current Ratio Ann.
-
-
-5.62.511.14.72.8
Interest Coverage Ratio Ann.
-
-
------
LT Debt To Equity Ann.
-
-
-0.200.1--
*All financials are in USD Million and price data in USD

Prime Medicine Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Prime Medicine Inc Dec-2025 Cash From Operating Activity is $-163 Million which is growth of -32.3% YoY.

  • NEGATIVE

    Net Cash Flow Prime Medicine Inc Dec-2025 Net Cash Flow is $-120 Million which is growth of -184.7% YoY.

Prime Medicine Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20
-
-
-162.6-122.9-165.4-131.8-34.1-5.5
-
-
-108.868.518.7-47.1-73.6-1.1
-5.8%
34.1%
151.5195.90.7181.5269.334.9
Cash Plus Cash Eqv. End Of Year Ann.
-27.5%
15.7%
76.7196.555.1201.1198.537
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-119.8141.5-146.12.6161.628.3
Cash Plus Cash Eqv. Begin Of Year Ann.
-0.3%
86.5%
196.555.1201.1198.5378.7
Income Tax Paid Supplemental Data Ann.
-
-
-----
Interest Paid Supplemental Data Ann.
-
-
------
Capex Ann.
-
-
-4.5-7.3-8.7-16.1-4.2-0.6
Issuance Of Capital Stock Ann.
-9.3%
31.6%
138.4170.1185.3270.435
Issuance Of Debt Ann.
-
-
------
Repayment Of Debt Ann.
-
-
------
Repurchase Of Capital Stock Ann.
-
-
------
Free Cash Flow Ann.
-
-
-167.1-130.2-174.1-147.9-38.2-6.2
*All financials are in USD Million and price data in USD
Cash from Financing Act. Ann.
1Y CHG
-22.7%
2Y CAGR
1371.2%
3Y CAGR
-5.8%
5Y CAGR
34.1%
Cash from Financing Annual Activity is falling faster than historical averages.